GeoVax Labs, Inc. (Nasdaq: GOVX) today announced financial results for the second quarter ended June 30, 2026, and provided a business update emphasizing continued progress toward the planned initiation of its pivotal GEO-MVA immunobridging study. The study, expected to begin in the fourth quarter, is being conducted under an expedited regulatory pathway established through Scientific Advice from the European Medicines Agency (EMA).
During the quarter, GeoVax advanced clinical operations planning, start-up activities, and manufacturing preparedness, including the utilization of previously manufactured cGMP clinical trial material. The company also progressed its AGE1 continuous cell-line manufacturing platform to support future commercial-scale MVA vaccine production and engaged with government and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GEO-MVA is GeoVax’s Modified Vaccinia Ankara (MVA)-based vaccine candidate for protection against mpox and smallpox. The company believes it is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity.
In its immuno-oncology program, GeoVax continues advancing Gedeptin, an investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin’s localized tumor-targeting mechanism may complement PD-1-based therapies by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578 for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5,369,783, or $8.74 per share, for the same period in 2025. The decrease in net loss was primarily due to lower research and development expenses, which fell to $3.1 million from $4.7 million, reflecting the discontinuation of activities related to the BARDA contract for its GEO-CM04S1 COVID-19 vaccine program. In April 2025, BARDA terminated the contract for convenience, and no comparable revenue was recognized in 2026. General and administrative expenses also decreased to $1.3 million from $1.5 million, attributable to lower investor relations consulting costs and reduced stock-based compensation.
As of June 30, 2026, GeoVax reported cash balances of approximately $3.1 million, consistent with the position at December 31, 2025. The company continues to prioritize capital deployment toward its lead programs, GEO-MVA and Gedeptin, and has discontinued active development of its GEO-CM04S1 COVID-19 vaccine candidate due to market contraction.
